HCS Pharma

HCS Pharma specializes in high-content screening (HCS) and high-content analysis (HCA) using advanced cell imaging technology for in vitro research and development. The company's flagship product is BIOMIMESYS, a unique hyaluronic acid-based 3D cell culture technology that reproduces the natural extracellular matrix (ECM) of different organs. The technology combines the advantages of both solid scaffolds and hydrogels to accurately mimic organ-specific cellular environments, enabling more predictive in vitro studies. Using BIOMIMESYS, HCS Pharma can create mini-organs from human cells to test new drug molecules, achieving up to 90% correlation between in vitro and in vivo results compared to just 3-10% with traditional research methods. The company's solution allows pharmaceutical companies to reduce drug development costs and timelines while improving the prediction of drug efficacy. In December 2017, HCS Pharma acquired and internalized the BIOMIMESYS technology from Celenys. The company works across multiple therapeutic areas including oncology, neurodegenerative diseases, and liver diseases. In July 2023, HCS Pharma entered into a cooperative agreement with Vidac Pharma to accelerate preclinical assays for anti-solid tumor drug candidates using the BIOMIMESYS platform.

Key customers and partnerships

HCS Pharma has established distribution agreements with partners in Japan, Taiwan, Europe and the US to strengthen its connections with pharmaceutical laboratories. The company has received letters of interest from major pharmaceutical companies including Servier and Sanofi. HCS Pharma collaborates with the Institut du Thorax Curie-Montsouris as part of the Chopin hospital-university research project. In March 2024, the company participated in ELRIG UK's Research and Innovation event to showcase its technology. The company also partners with Molecular Devices to integrate its 3D cell culture technology with automated imaging systems.